Federal Register of Legislation - Australian Government

Primary content

PB 49 of 2019 Arrangements as made
This instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) to add, delete and make changes to drugs, forms, brands, responsible person codes, maximum quantities/amounts and repeats and the circumstances for prescribing various pharmaceutical benefits (including authority requirements).
Administered by: Health
Registered 28 Jun 2019
Tabling HistoryDate
Tabled Senate02-Jul-2019
Tabled HR02-Jul-2019
To be repealed 17 Sep 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 49 of 2019

 

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 6)

 

National Health Act 1953

___________________________________________________________________________

 

I, BEN SLADIC, Assistant Secretary, Pharmacy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 100(2) of the National Health Act 1953.

 

Dated                   27 June 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BEN SLADIC

Assistant Secretary

Pharmacy Branch

Technology Assessment and Access Division

Department of Health

 


___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 6).

(2)          This Instrument may also be cited as PB 49 of 2019.

2          Commencement

This Instrument commences on 1 July 2019.

3          Amendment of National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011)

Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

 


Schedule 1       Amendments

[1]        Part 1, Division 1, Section 3, Definition for “diluent fee”

omit: $5.28             substitute: $5.35

[2]        Part 1, Division 1, Section 3, Definition for “dispensing fee”

omit: $7.29                 substitute: $7.39

[3]        Part 1, Division 1, Section 3, Definition for “distribution fee”

omit: $26.65               substitute: $27.02

[4]        Part 1, Division 1, Section 3, Definition for “preparation fee”

substitute:

preparation fee means an amount of $85.06.

Note:          The preparation fee includes $40 for compounding the dose of chemotherapy drug in the infusion, which is not indexed annually.  Where a TGA licensed compounder has compounded the dose of a chemotherapy drug, an additional TGA licensed compounding fee of $20 is payable to that TGA licensed compounder ‑ see section 46B.

[5]        Schedule 1, Part 1, entry for Pemetrexed in each of the forms: Powder for I.V. infusion 100 mg (as disodium); Powder for I.V. infusion 500 mg (as disodium); and Powder for I.V. infusion 1 g (as disodium)

omit from the column headed “Circumstances” (all instances): C4792 C7195

[6]        Schedule 4, omit entry for Pemetrexed